Previous 10 | Next 10 |
BeiGene (BGNE) announces that the China National Medical Products Administration has conditionally approved Kyprolis (carfilzomib) for injection in combination with dexamethasone for the treatment of adults with relapsed or refractory (R/R) multiple myeloma who have received at least two prio...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has conditionally approved KYPROLIS ® (carfilzomib)...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
The China National Medical Products Administration has accepted BeiGene's (BGNE) supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma ((ESCC)) who have disease progressi...
BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a ...
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. Zentalis Pharma, a US-China biopharma, closed a $150 million secondary offering to advance its small molecule cancer portfolio. Shanghai I-Mab announced it has achieved several clin...
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sander...
Shares in Chinese pharmaceutical company BeiGene (NASDAQ: BGNE) are up more than 34% this year, and more than 79% over the past 12 months. The company is coming off a strong first-quarter report, has two potential blockbuster cancer drugs in Brukinsa and Tislelizumab, and has lucrat...
JuSun/iStock via Getty Images During the week ended June 25, 2021, Healthcare sector rose 2.01% and Healthcare Select Sector SPDR ETF (XLV) gained 1.58% compared to weekly gain of 2.82% of S&P 500 ETF. Leading the top gainers pack was Atossa Therapeutics (ATO...
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. Jointech, a Hangzhou medical device company, has raised $62 million over the last 15 months to support its orthopedic surgery ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...